Targeting hypoxia-inducible factors: therapeutic opportunities and challenges
Read about strategies to activate or inhibit hypoxia-inducible factors to treat a range of diseases in this Review in the March issue
Read about strategies to activate or inhibit hypoxia-inducible factors to treat a range of diseases in this Review in the March issue
Bispecific antibodies (bsAbs) can mediate therapeutic effects beyond those of natural monospecific antibodies. This Review provides an overview of recent developments in the field of bsAbs for cancer therapy and an outlook into next-generation bsAbs in earlier stages of development.